Outcome (studies)
Improvement
Relative risk · 95% CI
00.511.5+
← Brilacidin
reduces riskIncreased
risk →
reduces riskIncreased
risk →
Brilacidin for COVID-19
1
study with
120
patients
Serious outcome risk
No significant improvements are seen in meta-analysis to date.
COVID-19 Brilacidin studies · November 2026
|
Outcome (studies)
Improvement
Relative risk · 95% CI
00.511.5+
← Brilacidin
reduces riskIncreased risk → |
Jul 30 2021 |
, NCT04784897 | A Phase 2, Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Brilacidin in Hospitalized Participants With COVID-19 |
| no change in mortality (p=1), 33% higher combined mortality/intubation (p=1), and 20% worse recovery (p=1). RCT 120 hospitalized COVID-19 patients showing no significant differences in pre-defined outcomes with brilacidin. | ||
